Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is currently 0.9 days.
Institutional Trading of Nanobiotix
Several hedge funds and other institutional investors have recently bought and sold shares of NBTX. Geode Capital Management LLC purchased a new stake in Nanobiotix in the 4th quarter worth approximately $29,000. Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter worth approximately $39,000. Jane Street Group LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at $73,000. Finally, OLD Mission Capital LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at $139,000. 38.81% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, UBS Group raised shares of Nanobiotix to a "hold" rating in a research note on Monday, February 17th.
Read Our Latest Research Report on Nanobiotix
Nanobiotix Stock Down 2.0 %
NBTX stock traded down $0.08 during midday trading on Thursday, hitting $3.73. The stock had a trading volume of 6,650 shares, compared to its average volume of 22,026. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51. The company's 50-day moving average price is $3.47 and its 200 day moving average price is $3.93.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
